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Anti-factor VIII (FVIII) inhibitory IgG may arise as alloantibodies to therapeutic FVIII in patients with
congenital hemophilia A, or as autoantibodies to endogenous FVIII in individuals with acquired
hemophilia. We have described FVIII-hydrolyzing IgG both in hemophilia A patients with anti-FVIII
IgG and in acquired hemophilia patients. Here, we compared the properties of proteolytic auto- and
allo-antibodies. Rates of FVIII hydrolysis differed signiﬁcantly between the two groups of antibodies.
Proline-phenylalanine-arginine-methylcoumarinamide was a surrogate substrate for FVIII-hydro-
lyzing autoantibodies. Our data suggest that populations of proteolytic anti-FVIII IgG in acquired
hemophilia patients are different from that of inhibitor-positive hemophilia A patients.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Acquired hemophilia is a rare bleeding disorder, caused by the
spontaneous occurrence of autoantibodies directed against endog-
enous factor VIII (FVIII) that inhibit the procoagulant activity of
FVIII and are referred to as FVIII inhibitors [1]. About 50% of the
cases are associated with underlying pathological conditions. The
remaining cases arise during the post-partum period or are
idiopathic. FVIII inhibitors also arise in patients with congenital
hemophilia A as alloantibodies directed to therapeutically admin-
istered exogenous FVIII in the course of replacement therapy [2].
Autoantibodies and alloantibodies against FVIII share similar
properties [3,4], but may differ in their kinetics of FVIII inactivation
[5].chemical Societies. Published by E
872 Equipe 16, Centre de
ine, 75006 Paris, France. Fax:
ieu.fr (S. Lacroix-Desmazes).We have reported that IgG from hemophilia A patients and from
patients with acquired hemophilia both may hydrolyze FVIII [6,7].
In the case of hemophilia A, FVIII-hydrolyzing IgG were detected in
50% of inhibitor-positive patients [8]. FVIII-hydrolyzing IgG from
these patients inactivated FVIII with kinetics of FVIII degradation
that are compatible with a pathogenic role towards therapeutical
FVIII [9]. The rates of IgG-mediated FVIII hydrolysis correlated with
the inhibitory activity measured in patients’ plasma. Cleavage sites
for IgG on FVIII were spread over the heavy and light chains of
FVIII. In the case of acquired hemophilia, autoimmune FVIII-hydro-
lyzing IgG were found in 47% of the patients [7]. We failed to ﬁnd a
correlation between the rates of IgG-mediated FVIII hydrolysis and
the inhibitory titer in plasma or the survival of the patients one
year following diagnosis of the disease. The levels of IgG-mediated
FVIII hydrolysis co-evolved with the inhibitory titers measured
during the course of the treatment [7].
Here, we decipher the properties of auto-immune FVIII-hydro-
lyzing IgG and compare them to that of alloimmune FVIII-hydro-
lyzing IgG. The data suggest that populations of FVIII-hydrolyzinglsevier B.V. All rights reserved.
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ical situation that prevails when they are generated.2. Materials and methods
2.1. Patients
Plasma samples from 45 patients with acquired hemophilia
were obtained from CHU de Rouen (Etude Sacha), Caen, Compiè-
gne, from Hôpital Cochin (Paris), Hôpitaux du Kremlin-Bicêtre
(Bicêtre) and Rennes (France), in accordance with the local ethical
regulation. Patients’ clinical characteristics included in the cohort
have been published [7]. Plasma was obtained at the time of diag-
nosis. Age at time of diagnosis was 68.3 ± 17.6 years (mean ± S.D.,
ranging from 25 to 92). Patients included 28 males and 13 females
(not documented in the case of 4 patients). Inhibitory titer and
residual FVIII activity in plasma at time of diagnosis were
84.1 ± 174.0 BU/ml and 5.6 ± 6.2%, respectively. Survival one year
after diagnosis, documented for 35 patients, was 60%. In the case
of 8 patients, blood samples were obtained sequentially over peri-
ods of 6–140 days. For these 8 patients, the underlying treatments
included cortico-therapy, therapeutic FVIII, recombinant activated
factor VII and/or intravenous immunoglobulins (IVIg).
2.2. IgG puriﬁcation
IgG was isolated from plasma on protein G Sepharose (Amer-
sham). A therapeutic preparation of pooled normal human immu-
noglobulin (IVIg, Sandoglobulin, CSL-Behring, Switzerland) was
used as a source of normal IgG. To exclude potentially contaminat-
ing proteases, size-exclusion chromatography of patients’ IgG and
IVIg was performed on a superose-12 column (Amersham) equili-
brated with 50 mM Tris, 8 M urea and 0.02% NaN3 (pH 7.7), at a
ﬂow rate of 250 ll/min. IgG was dialyzed against PBS–0.01%
NaN3 for 48 h at 4 C, followed by dialysis against 50 mM Tris
(pH 7.7), 100 mM glycine, 0.02% NaN3, 5 mM CaCl2 (catalytic buf-
fer) for 24 h at 4 C.
2.3. Hydrolysis of biotinylated antigens
Commercially available recombinant human FVIII (Kogenate
FS, Bayer HealthCare, France) and activated factor VII (FVIIa, Novo-
Seven, Novo Nordisk, Chartres, France) were biotinylated [7]. Bio-
tinylated FVIII and FVIIa (185 nM) were incubated in catalytic
buffer with IgG (67 nM) for 24 h at 37 C. Samples were subjected
to 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
followed by Western blotting and detection using streptavidin-
coupled alkaline phosphatase (KPL, Gaithersburg, MD, USA) and
the BCIP/NBT substrate. The rates of hydrolysis of FVIII were mea-
sured as described [7]. Results were expressed as millimoles of
FVIII protein hydrolyzed per minute per moles of IgG. Signiﬁcant
differences between the rates of hydrolysis by patients’ IgG and
by IVIg were assessed using an ANOVA post hoc test (Ficher PLSD).
Reported P values are one-sided.
2.4. Pro-Phe-Arg-MCA hydrolysis
IgG (67 nM) was mixed with proline-phenylalanine-arginine-
methylcoumarinamide (PFR-MCA, Peptide Inc., Osaka, Japan) at
100 lM in 40 ll catalytic buffer and incubated in the dark for
24 h at 37 C. Hydrolysis was determined by the ﬂuorescence of
the leaving group (aminomethylcoumarin; kem 465 nm, kex
360 nm). Fluorescence values were compared to a standard curve
of free MCA to compute corresponding quantities of released
MCA. At each time point, background release of MCA, measuredfor each PFR-MCA concentration in wells containing the substrate
alone, was subtracted from the value observed in the presence of
the antibodies.
2.5. Calculation of Ki
IgG (67 nM) was incubated with 60, 120 and 180 lM of PFR-
MCA in the presence of increasing amount of FVIII (0.013–
3.3 lM), for 24 h at 37 C. For each FVIII concentration, a double re-
ciprocal graph was plotted: the reciprocal of the rate of PFR-MCA
hydrolysis versus that of the substrate concentration (PFR-MCA).
The slopes of the curves were calculated by linear regression anal-
ysis, and plotted as a function of inhibitor concentration (i.e., FVIII).
Intersection with the X-axis of the linear regression curve obtained
with the latter data, indicates the Ki value.
2.6. Determination of the quantity of catalytic antibodies in plasma
IgG from patients 1, 2, 15, 20, 22, 38, 42, 43, 45 were allowed to
react with Pefabloc (0–0.05 lM) (Roche Diagnostics, Mannheim,
Germany), an irreversible inhibitor of serine proteases, for 1 h at
37 C. Mixtures were incubated with PFR-MCA (100 lM) for 24 h
at 37 C. Residual PFR-MCA hydrolysis was measured. Inhibition
data (total inhibition values) obtained were curve-ﬁtted to obtain
single linear regression curves that represent IgG with low PFR-
MCA hydrolyzing activity (QL). Values calculated from the linear
regression curve at each Pefabloc concentration were subtracted
from total inhibition values; obtained data were curve-ﬁtted to ob-
tain a second single linear regression curve that represents IgG
with high PFR-MCA hydrolyzing activity (QH). Theoretically, the
amount of inhibition by Pefabloc is a reﬂection of the quantity
of catalytic sites in the IgG pool. Intersection of each generated
regression curve with the X-axis indicates the amounts of IgG with
low and high PFR-MCA hydrolyzing activity, respectively.3. Results
3.1. IgG from patients with acquired hemophilia hydrolyze FVIII
Hydrolytic patterns of FVIII and FVIIa incubated in buffer alone
or with puriﬁed IgG from ﬁve patients are depicted in Fig. 1A. FVIII
(185 nM) incubation with IgG (67 nM) from patients 2, 10, 16 and
32 resulted in FVIII hydrolysis. The FVIII migration proﬁle exhibited
minimal spontaneous degradation when it was incubated in buffer
alone (Ctl). In parallel, trypsin (>0–41.7 nM) incubated with FVIII
displayed a different hydrolytic pattern as compared to that of FVIII
hydrolysis by IgG (data not shown). IgG from acquired hemophilia
patients did not hydrolyze FVIIa or human serum albumin (Fig. 1A
and [7]). Speciﬁc rates of FVIII hydrolysis by the IgG from 45 ac-
quired hemophilia patients were calculated using the densitomeric
analysis of the hydrolyzed bands. IVIg exhibited a hydrolytic activ-
ity of 0.06 ± 0.03 mmol/min/mol (Table 1 and Fig. 1E). IgG from 21
of the 45 patients (46.6%) exhibited a FVIII-hydrolyzing activity
signiﬁcantly higher than that of IVIg (Table 1, P < 0.05). The mean
hydrolytic activity of IgG of these 21 patients was
0.22 ± 0.09 mmol/min/mol (coefﬁcient of variation: 0.29 ± 0.20)
[7].
3.2. IgG-mediated PFR-MCA hydrolysis correlates with rates of FVIII
hydrolysis
An excess of FVIII neutralized in a dose-dependent manner the
auto-immune IgG-mediated hydrolysis of PFR-MCA (Fig. 1B). The
Ki calculated in the case of IgG from patient 1 was
4.45 ± 0.49 lM. An excess of PFR-MCA inhibited FVIII hydrolysis
Fig. 1. (Panel A) Hydrolysis of FVIII by IgG puriﬁed from the plasma of patients with acquired hemophilia. Biotinylated FVIII and FVIIa (185 nM) were incubated alone (Ctl) or
in the presence of IgG (67 nM) from patients 2, 10, 16, 20 and 32 for 24 h at 37 C. IVIg was used as a source of normal IgG and as a negative control. Migration proﬁles on a
10% SDS–PAGE are depicted. (Panel B) Inhibition of hydrolysis of PFR-MCA by puriﬁed IgG in the presence of FVIII. IgG (67 nM) from patient 1 was allowed to react with
increasing concentrations of FVIII (0–3.3 lM) for 30 min at 37 C. The mixtures were then incubated in the presence of PFR-MCA (60 lM) for 24 h at 37 C. The ﬁgure depicts
the inhibition of IgG-mediated PFR-MCA hydrolysis in the presence of FVIII, measured in two independent experiments. The Ki was calculated as described in the materials
and methods and was equal to 4.45 ± 0.49 lM. (Panels C and D) Correlation between the hydrolysis of FVIII and PFR-MCA by IgG from patients’ IgG. Biotinylated FVIII
(185 nM) and the peptide PFR-MCA (100 lM) were incubated alone or in the presence of IVIg or of IgG (67 nM) puriﬁed from the plasma of 45 patients with acquired
hemophilia (Panel C) or 22 patients with congenital hemophilia A (Panel D, [9]), for 24 h at 37 C. Rates of hydrolysis of FVIII and of PFR-MCA were calculated as explained in
Materials and Methods and are expressed as mmoles of substrate hydrolyzed per min per moles of IgG. Data were plotted for all patients (open squares and circles). In each
panel, the solid curve represents the linear regression analysis of the data. The signiﬁcance of the correlations between the FVIII- and PFR-MCA-hydrolyzing activities were
assessed using the nonparametric Spearman rank correlation. (Panels E and F) IgG-mediated hydrolysis of FVIII and of PFR-MCA. Rates of hydrolysis of FVIII (Panel E) and of
PFR-MCA (Panel F) were measured in the case of IgG puriﬁed from the plasma of 45 patients with acquired hemophilia, 22 patients with congenital hemophilia A and 9
healthy donors (panel E, 10 healthy donors in the case of panel F). Hydrolysis mediated by IVIg in the case of both substrates is indicated. The thick lines represent the
arithmetic means and the thin lines the standard deviations. Signiﬁcance between differences were assessed using the nonparametric Mann–Whitney test.
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Table 1
Speciﬁc rates of hydrolysis of FVIII and of PFR-MCA by IgG puriﬁed from the plasma of 45 patients with acquired hemophilia.
Patient number Inhibitory titer in plasmaa (BU/ml) Hydrolysis of FVIIIb (mmol/min/mol) Hydrolysis of PFR-MCAc (mmol/min/mol)
1 40 0.45 ± 0.2* 3.78 ± 1.4*
2 63 0.15 ± 0.0 4.34 ± 0.5*
3 128 0.14 ± 0.1 2.00 ± 0.9*
4 114 0.13 ± 0.1 1.31 ± 0.7*
5 380 0.17 ± 0.0 0.57 ± 0.1
6 32 0.12 ± 0.1 0.82 ± 0.6*
7 49.4 0.08 ± 0.0 0.96 ± 0.1*
8 3.1 0.38 ± 0.2* 5.68 ± 1.8*
9 42 0.13 ± 0.0 1.08 ± 0.1*
10 6 0.17 ± 0.0 0.71 ± 0.1*
11 14 0.08 ± 0.0* 0.55 ± 0.1*
12 2 0.12 ± 0.1 2.61 ± 0.8*
13 40 0.16 ± 0.1* 0.78 ± 0.7
14 2 0.22 ± 0.0* 3.56 ± 0.6*
15 80 0.18 ± 0.0* 6.90 ± 0.6*
16 52 0.14 ± 0.0* 1.86 ± 0.2*
17 100 0.36 ± 0.1* 3.74 ± 0.7*
18 10 0.09 ± 0.0 1.57 ± 0.3*
19 1.4 0.10 ± 0.0 1.84 ± 0.1*
20 18 0.08 ± 0.0 5.96 ± 0.9*
21 1050 0.15 ± 0.1* 2.94 ± 0.3*
22 330 0.14 ± 0.1* 2.95 ± 1.1*
23 18 0.30 ± 0.1* 4.12 ± 0.7*
24 1.3 0.05 ± 0.0 2.94 ± 0.5*
25 60 0.06 ± 0.0 5.14 ± 0.2*
26 1 0.06 ± 0.0 1.75 ± 0.8*
27 4 0.10 ± 0.1 1.16 ± 0.3*
28 56 0.07 ± 0.0 1.54 ± 0.1
29 4.5 0.13 ± 0.0* 0.77 ± 0.2*
30 1.5 0.08 ± 0.0 0.62 ± 0.2*
31 3 0.11 ± 0.1* 0.53 ± 0.0
32 7 0.19 ± 0.0* 7.17 ± 0.3*
33 362.7 0.08 ± 0.0 2.16 ± 0.1*
34 249.2 0.09 ± 0.1 1.19 ± 0.3*
35 62 0.32 ± 0.0* 3.31 ± 0.1
36 54 0.21 ± 0.1* 2.47 ± 0.1*
37 1 0.13 ± 0.1* 0.78 ± 0.2*
38 105.4 0.10 ± 0.0 1.24 ± 0.3*
39 92.5 0.09 ± 0.0 0.65 ± ± 0.2
40 26.6 0.10 ± 0.1 1.36 ± 0.2*
41 10 0.17 ± 0.0* 2.83 ± 0.6*
42 29.9 0.10 ± 0.0 1.48 ± 0.1*
43 4.9 0.30 ± 0.2* 3.13 ± 1.3*
44 13 0.10 ± 0.0 1.97 ± 0.1*
45 58.2 0.17 ± 0.0* 1.71 ± 0.3*
IVIg 0 0.06 ± 0.03 0.06 ± 0.03
a Inhibitory titers were measured in the plasma using the Bethesda assay.
b The results are mean ± S.D. of four independent experiments. Rates of factor VIII hydrolysis were calculated by densitometric analysis of Western blots. Spontaneous
hydrolysis that occurred upon incubation of factor VIII in the presence of buffer alone was subtracted from each analysis. The mean coefﬁcient of variation was 0.37 ± 0.21
(coefﬁcients of variation vary between 0.05 and 0.92).
c The results are mean ± S.D. of ﬁve independent experiments. Spontaneous hydrolysis that occurred upon incubation of PFR-MCA in the presence of buffer alone was
subtracted from each analysis. The mean coefﬁcient of variation was 0.37 ± 0.21 (coefﬁcients of variation vary between 0.05 and 0.92).
* P < 0.05 for the comparison with intravenous immunoglobulin (IVIg), using an analysis of variance post hoc test.
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PFR-MCA hydrolysis of patients’ IgG was 2.4 ± 1.7 mmol/min/mol
(Table 1 and Fig. 1F). IgG from 35 patients (77.8%) displayed signif-
icantly higher hydrolytic rates of PFR-MCA than IVIg
(0.06 ± 0.03 mmol/min/mol, P < 0.05). FVIII hydrolysis rates and
PFR-MCA hydrolysis rates by IgG from the 45 patients were posi-
tively correlated (Fig. 1C, Spearman rank correlation, rho = 0.395,
P = 0.008), which was not the case for IgG from 22 with hemophilia
A patients (Fig. 1D, rho = 0.05, P = 0.8, [9]). Taken together, the re-
sults suggest that PFR-MCA is a suitable alternative substrate for
autoimmune FVIII-hydrolyzing IgG.
3.3. Kinetics of PFR-MCA hydrolysis by catalytic antibodies
Using PFR-MCA as a substrate, we quantiﬁed the number of en-
zyme active sites in the polyclonal pool of IgG from patients with
acquired hemophilia. Co-incubation of PFR-MCA with IgG from pa-tient 20 with the protease inhibitors E-64 (28 lM), EDTA (1.3 lM),
or pepstatin (10 lM) did not inhibit the hydrolytic activity. Con-
versely, aprotinin (0.3 lM), leupeptin (100 lM) and Pefabloc
(100 lM) inhibited in a dose-dependent way PFR-MCA hydrolysis,
suggesting that IgG possess serine protease-like activity (data not
shown). In order to calculate the enzyme active sites in the IgG pool,
5.3 pmoles of IgG from patients 1, 2, 15, 20, 22, 38, 42, 43 and 45
were reacted with Pefabloc (0–0.05 lM) prior to incubation with
PFR-MCA (100 lM) (Fig. 2A). IgG with low and high catalytic activ-
ity represented approximately 53 ± 11% and 9 ± 4% of total IgG,
respectively (Table 2, calculated as explained in Section 2).
Incubation of patients’ IgG (67 nM) with increasing concentra-
tions of PFR-MCA (0–2 mM) led to the saturation of hydrolytic
activity towards PFR-MCA (Fig. 2B for IgG from patient 2). Fitting
the experimental data to Michaelis–Menten equation allowed der-
ivation of the apparent Vmax and average Km of the reactions (Table
3). The computed kinetic parameters were heterogeneous among
Fig. 2. (Panel A) Quantiﬁcation of IgG with serine protease activity within the
polyclonal pool of IgG from a patient with acquired hemophilia. The IgG puriﬁed
from the plasma of patient 2 was allowed to react with increasing concentrations of
Pefabloc prior to be incubated in the presence of PFR-MCA. The obtained data were
ﬁtted to a double linear regression model to obtain the quantity of catalytic IgG
with high PFR-MCA-hydrolyzing activity (QH) and the quantity of catalytic IgG with
low PFR-MCA-hydrolyzing activity (QL),as explained in Section 2. (Panels B and C)
Kinetic parameters of PFR-MCA hydrolysis. PFR-MCA (0-2 mM) was incubated in
the presence of IgG from patient 2 (Panel B, 66.6 nM) or trypsin (Panel C, 0.42 nM)
for 24 h at 37 C. The plotted values represent the rate of hydrolysis of PFR-MCA
determined at each concentration of PFR-MCA. The solid curve depicts the ﬁt of the
experimental data to the Michaelis–Menten equation.
Table 2
Quantity of catalytic IgG within the polyclonal pool of total IgG from patients with
acquired hemophilia.
Patients’
IgG
Quantity of PFR-MCA hydrolyzing IgG
Low hydrolyzing activity, pmol
(%)
High hydrolyzing activity,
pmol (%)
1 3.0 (56) 0.4 (8)
2 2.3 (43) 0.5 (10)
15 2.4 (44) 0.5 (10)
20 2.7 (51) 0.3 (7)
22 3.1 (59) 0.3 (6)
38 3.5 (66) 0.2 (3)
42 2.1 (40) 0.2 (5)
43 2.5 (48) 0.7 (14)
45 3.9 (73) 0.8 (15)
Mean ± S.D. 2.84 ± 0.58 (53 ± 11) 0.46 ± 0.21 (9 ± 4)
The values are expressed as pmoles of catalytic IgG per 5.3 pmoles of puriﬁed
polyclonal total IgG. Values in round brackets represent the mean % of catalytic IgG
with low and high activity. The results are representative of three individual
experiments.
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average Km of 427.4 ± 143.6 lM. Kinetic parameters of PFR-MCA
hydrolysis were also calculated for a model serine protease, tryp-sin, tested at 0.42 nM (Fig. 2C). Vmax and Km for trypsin were
201.4 ± 3.6 fmol/min and 414.6 ± 10.0 lM. The average computed
catalytic efﬁciencies calculated on the basis of the proportion of
IgG with catalytic activity (60.6 ± 60.3 M1 min1) in the pool of
polyclonal IgG showed a 477-fold difference with that of trypsin
(28 922.3 M1 min1), thus providing evidence for the lack of con-
tamination by conventional serine proteases among the puriﬁed
polyclonal IgG preparations. Based on the derived Kcat values, cat-
alytic IgG cleaved 5–114 molecules of PFR-MCA in 24 h, indicating
capacity of turnover.
3.4. Evolution with time of the catalytic activity of IgG
We have demonstrated previously that 3/4 patients followed
over the course of the disease had FVIII hydrolysis rates that co-
evolved with inhibitory titers in plasma, suggesting that IgG-med-
iated FVIII hydrolysis participates in part in FVIII inactivation. Here,
we followed eight patients over the course of the disease. Plasma
was collected at the time of diagnosis and during the course of
the disease for periods of time ranging from 6 to 140 days. At the
time of diagnosis, inhibitory titers in plasma were 42, 6, 14, 2,
60, 56, 7 and 62 BU/ml, respectively (Table 1). At the time of the
last sampling, all patients had detectable inhibitory titers of 18,
0.7, 3.5, 0.6, 30, 67, 1.6 and 19 BU/ml, respectively (Fig. 3). Thus,
in the case of 7 patients, inhibitory titers had decreased by 2.0–
8.6-folds, while one patient presented with a steady inhibitory titer
(patient 28). IgG was puriﬁed from each of the plasma samples and
assessed for serine protease activity towards PFR-MCA. At the time
of diagnosis, hydrolytic activities of IgG from patients 9, 10, 11, 14,
25, 28, 32 and 35, were 1.08, 0.71, 0.55, 3.56, 5.14, 1.54, 7.17 and
3.31 mmol/min/mol, respectively (Table 1). At the time of the last
sampling, the hydrolytic activities of patients’ IgG were 1.72, 0.43,
0.79, 4.62, 0.84, 1.51, 2.99 and 1.51 mmol/min/mol (Fig. 3), respec-
tively. Thus, in the case of 4 patients, the hydrolytic activity of IgG
had decreased by 3.1 ± 2.0-folds. IgG from the remaining patients
demonstrated stable (patient 28) or increased (patients 9, 11 and
14) hydrolytic activities. Overall, hydrolysis rates of PFR-MCA
and Bethesda titers in plasma evolved following similar trends in
the case of 6 patients (Fig. 3).
4. Discussion
While inhibition of FVIII by IgG-mediated hydrolysis is a feature
shared by allo- and auto-antibodies to FVIII, FVIII-hydrolyzing
alloantibodies presented heterogeneous FVIII hydrolysis rates,
Table 3
Kinetic parameters of the hydrolysis of PFR-MCA by IgG of patients with acquired hemophilia.
Patients/Control Vmaxa (fmol/min) Kmb (lM) Kcatc (min1) Catalytic efﬁciencyd (M min)1
1 46.1 ± 7.7 376.4 ± 169.8 0.013 38.5
2 74.9 ± 14.2 500.4 ± 90.9 0.027 53.6
15 111.9 ± 5.1 466.7 ± 33.2 0.039 83.1
20 112.5 ± 12.6 545.5 ± 152.5 0.037 69.4
22 20.1 ± 2.5 163.0 ± 38.1 0.004 24.0
38 31.8 ± 6.8 273.4 ± 178.7 0.005 21.1
42 189.5 ± 11.6 399.7 ± 118.4 0.079 209.6
43 41.0 ± 17.3 484.3 ± 391.5 0.013 31.2
45 44.0 ± 6.0 637.2 ± 170.0 0.009 15.2
Trypsin 201.4 ± 3.6 414.6 ± 10.0 12.0 28 922.3
a,b PFR-MCA was incubated at increasing concentrations (0–2 mM) with IgG (67 nM) of nine patients with acquired hemophilia or of trypsin (0.42 nM), for 24 h at 37 C.
Hydrolysis rates were computed as explained in Materials and Methods. The data were ﬁtted to the Michaelis–Menten equation (r2P 0.94) and Vmax and Km were derived.
The data represent the mean of three independent experiments.
c In the calculation of Kcat, in the case of patients’ IgG, the quantity of catalytic IgG sites within the pool of IgG was estimated to be equal to 3.3 ± 0.8 pmol per 5.3 pmol
(Table 2).
d The catalytic efﬁciency is the ratio of Kcat to the corresponding Km.
Fig. 3. Follow-up of the inhibitory and hydrolytic activities of patients’ IgG. Plasma samples were collected from eight patients with acquired hemophilia during periods of
time comprised between 6 and 150 days. Four to 7 samples were collected for each patient. For each sample, the inhibitory titer towards FVIII was measured in plasma (BU/
ml, closed circle). IgG was puriﬁed from each plasma sample and assessed for PFR-MCA hydrolysis (mmol/min/mol, open circle). The graphs depict for each of the 8 patients
the evolution with time of the inhibitory titer (left y-axis) and of the rates of IgG-mediated PFR-MCA hydrolysis (right y-axis).
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those measured for FVIII-hydrolyzing autoantibodies (Fig. 1E,
P = 0.033). Previous studies have failed to distinguish FVIII inhibi-
tory IgG that arise under autoimmune conditions from those that
develop in an alloimmune context, with respect to the isotypic dis-
tribution and to the epitopes targeted on FVIII [3–5,10]. Anti-FVIII
allo- and autoantibodies have however been found to differ in their
kinetics of FVIII inactivation, and capacity to be neutralized by
anti-idiotypic antibodies (reviewed in [11]), suggesting the exis-
tence of subtle differences in the epitopes recognized by the two
groups of antibodies and in the structures of their variable regions.
Whether such differences account for the differences in FVIII
hydrolysis rates of allo- and auto-immune IgG remains hypotheti-
cal. Alternatively, the differences in proteolytic behavior of allo-
and auto-antibodies may reﬂect the different immunological
contexts under which FVIII-hydrolyzing IgG have been generated.
In particular, while development of anti-FVIII alloantibodies mayresult from the inability of the patients’ immune system to estab-
lish tolerance to a harmless exogenous antigen [12], appearance of
anti-FVIII autoantibodies results from a break in tolerance to an
endogenous molecule.
Our initial attempts to determine the kinetic parameters of
FVIII-hydrolyzing IgG were hindered by the limited maximal con-
centration of FVIII available. To overcome this limitation, we have
used a generic tri-peptide synthetic substrate, PFR-MCA [9], previ-
ously used to screen catalytic IgG, directed against antigen sub-
strates such as vasoactive intestinal peptide [13] and
thyroglobulin [14]. The cleavage of the amide bond between the
amino acid arginine and the ﬂuorescent moiety MCA justiﬁes for
a peptide bond hydrolysis, but may not essentially mimic the
hydrolysis of a complex protein antigen. Indeed, alloimmune
FVIII-hydrolyzing antibodies did not present a signiﬁcant correla-
tion between FVIII and PFR-MCA hydrolysis rates. Conversely, in
the case of autoimmune FVIII-hydrolyzing IgG, and despite the
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autoimmune FVIII inhibitors, the FVIII hydrolysis rates correlated
with PFR-MCA hydrolysis rates. The apparent Vmax
(74.7 ± 54.4 fmol/min) and average Km (427.4 ± 143.6 lM) calcu-
lated for PFR-MCA hydrolysis in the case of IgG from nine patients
with acquired hemophilia, differed from that previously published
for ﬁve hemophilia A patients (12.7 ± 4.0 fmol/min and
846.6 ± 351.6 lM, respectively) [9], possibly accounting for the
above mentioned discrepancy. However, the estimated Kcat
(0.05 ± 0.02 min1 in the case of alloantibodies [9] and
0.03 ± 0.02 min1 in that of autoantibodies) and the average cata-
lytic efﬁciencies (71 ± 32 and 61 ± 60 M1 min1, respectively)
did not allow to discriminate between the two groups of patients.
Recently, we described the co-evolution of the titers of IgG-
mediated FVIII hydrolysis with the inhibitory titers measured in
the plasma of acquired hemophilia patients during the course of
the treatment. Here, we have performed a follow-up study in the
case of eight patients. In the case of 6 out of 8 patients, we ob-
served similar trends of co-evolution between the catalytic activity
of IgG measured towards PFR-MCA and the measured Bethesda ti-
ters in plasma. The data demonstrate the reliability of PFR-MCA as
a surrogate substrate for autoimmune FVIII-hydrolyzing IgG, and
highlight the different natures of FVIII-hydrolyzing allo- and
auto-antibodies.
Paul et al., reported that IgG from patients with systemic lupus
erythematosis (SLE) and autoimmune thyroiditis (ATh), presented
with signiﬁcantly increased thyroglobulin-cleaving activities, as
compared to IgG from healthy individuals or from patients with
asthma or HIV infection [15]. Conversely, PFR-MCA hydrolysis
was detected among IgG from healthy donors, but was extremely
low or undetectable among IgG from SLE, ATh and rheumatoid
arthritis patients [15,16]. Here, we document that IgG from alloim-
mune and autoimmune patients are endowed with greater levels
of hydrolysis towards both FVIII and PFR-MCA, than IgG from
healthy donors. Our results conﬁrm that pathological conditions,
whether alloimmune or autoimmune, are associated with in-
creased levels of proteolytic IgG targeted towards cognate anti-
gens. They however do not support the hypothesis of a universal
occurrence of polyspeciﬁc catalytic activity in healthy donors that
diminishes under autoimmune/inﬂammatory conditions.
We have previously reported on the absence of contaminating
proteases among IgG puriﬁed from the serum of the different pa-
tients, that would account for the observed proteolysis of the dif-
ferent substrates [7]. Here, we have compared the data on the
modiﬁcation rates of puriﬁed catalytic IgG from patients to that
of a conventional serine protease, trypsin. There was a 2.7-fold dif-
ference in the apparent Vmax calculated between patients’ IgG and
trypsin (Table 3), while average Km were in the same range. The
catalytic efﬁciencies, calculated on the basis of the proportion of
IgG with high catalytic activity in the polyclonal IgG pool, showed
a 477-fold difference between patients’ IgG and trypsin. Taken to-
gether, the data indicate that the modiﬁcation rates calculated for
puriﬁed IgG in our assay widely differ from that calculated for a
conventional serine protease, thus suggesting that the architecture
of the active site of FVIII-hydrolyzing molecules in our prepara-
tions is different from that of a conventional enzyme.
The occurrence of FVIII-hydrolyzing IgG has been reported in
patients with hemophilia A [6], acquired hemophilia [7], sepsis
[17] and renal transplantation [18]. FVIII-hydrolyzing IgG may thus
be endowed with pathological roles; in inhibitor-positive patients
with congenital hemophilia A, they inactivate therapeutic FVIII and
hamper the control of hemorrhage. Alternatively, IgG-mediated
FVIII hydrolysis may be beneﬁcial in other pathological situations.
Thus, patients with sepsis develop disseminated intravascular
coagulation that may lead to organ failure [19]. Similarly, in pa-
tients with kidney transplant, uncontrolled activation of coagula-tion by the stressed endothelium of the graft is thought to play a
role in the pathophysiology of chronic allograft nephropathy [20–
22]. In both situations, IgG-mediated FVIII inactivation, within lim-
its that are compatible with normal coagulation, may be beneﬁcial
by disrupting the ampliﬁcation loop of thrombin generation which
is dependent, at least in part, on factor VIII. The identiﬁcation of the
molecular immunological mechanisms underlying the selection of
B lymphocytes secreting FVIII-hydrolyzing IgG under such a vari-
ety of pathological conditions remains the subject of intense
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